512 related articles for article (PubMed ID: 7964124)
21. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
22. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
Ponka P; Schulman HM; Wilczynska A
Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
24. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
25. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes.
Ponka P; Richardson D; Baker E; Schulman HM; Edward JT
Biochim Biophys Acta; 1988 Oct; 967(1):122-9. PubMed ID: 3167093
[TBL] [Abstract][Full Text] [Related]
26. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
Buss JL; Arduini E; Shephard KC; Ponka P
Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
[TBL] [Abstract][Full Text] [Related]
27. Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin.
Watts RN; Richardson DR
J Lab Clin Med; 2000 Aug; 136(2):149-56. PubMed ID: 10945243
[TBL] [Abstract][Full Text] [Related]
28. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
29. The release of iron and transferrin from the human melanoma cell.
Richardson DR; Baker E
Biochim Biophys Acta; 1991 Feb; 1091(3):294-302. PubMed ID: 2001412
[TBL] [Abstract][Full Text] [Related]
30. Brain iron homeostasis.
Moos T
Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
[TBL] [Abstract][Full Text] [Related]
31. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
32. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
Johnson DK; Pippard MJ; Murphy TB; Rose NJ
J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
[TBL] [Abstract][Full Text] [Related]
33. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Le NT; Richardson DR
Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
[TBL] [Abstract][Full Text] [Related]
34. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
Webb J; Vitolo ML
Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
[No Abstract] [Full Text] [Related]
35. Transferrin-bound and transferrin free iron uptake by cultured rat astrocytes.
Qian ZM; Liao QK; To Y; Ke Y; Tsoi YK; Wang GF; Ho KP
Cell Mol Biol (Noisy-le-grand); 2000 May; 46(3):541-8. PubMed ID: 10872741
[TBL] [Abstract][Full Text] [Related]
36. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
Vitolo ML; Clare BW; Hefter GT; Webb J
Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
[No Abstract] [Full Text] [Related]
37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
Gao J; Richardson DR
Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
Fan L; Iyer J; Zhu S; Frick KK; Wada RK; Eskenazi AE; Berg PE; Ikegaki N; Kennett RH; Frantz CN
Cancer Res; 2001 Feb; 61(3):1073-9. PubMed ID: 11221835
[TBL] [Abstract][Full Text] [Related]
39. Tritrichomonas foetus: iron acquisition from lactoferrin and transferrin.
Tachezy J; Kulda J; Bahníková I; Suchan P; Rázga J; Schrével J
Exp Parasitol; 1996 Jul; 83(2):216-28. PubMed ID: 8682190
[TBL] [Abstract][Full Text] [Related]
40. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
